FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165167941> ?p ?o ?g. }

• W2165167941 endingPage "28" @default.
• W2165167941 startingPage "24" @default.
• W2165167941 abstract "To assess whether cyclosporin A has any influence on the bones of patients with primary biliary cirrhosis, bone mineral density, vertebral fractures and biochemical and hormonal parameters of bone mineral metabolism were evaluated in 38 female patients with primary biliary cirrhosis who, 7 to 47 months previously, had been randomized to receive cyclosporin A (n=18) or placebo (n=20). Bone mineral density and vertebral fractures were reevaluated after 12 to 47 months in 19 of these patients (ten with cyclosporin and nine with placebo). Serum osteocalcin levels in patients taking cyclosporin (median, range: 7.8, 4.2–16 ng/ml) were similar to healthy female controls (6.0, 4.7–9.5 ng/ml), and significantly higher than in patients receiving placebo (5.4, 1.0–8.6 ng/ml, p<0.02). Patients treated with cyclosporin showed a higher urinary hydroxyproline/creatinine ratio (0.097, 0.025–0.138) than patients with placebo (0.031, 0.022–0.044) (0.05>p<0.1), and healthy controls (0.032, 0.021–0.048) (p<0.001). Urinary hydroxyproline was above normal levels in six of nine patients treated with cyclosporin. Circulating parathyroid hormone levels were also higher in patients treated with cyclosporin (4.3, 2.0–9.0 pmol/l) than in those with placebo (3.1, 1.1–5.1 pmol/l) (p<0.001), and healthy controls (2.9, 1.1–6.9 pmol/1) (p<0.001). In four patients treated with cyclosporin the parathyroid hormone levels were above normal values. No patient had renal failure. Among the 19 patients who were studied on two occasions, no significant bone mineral density changes were observed in ten patients treated with cyclosporin (1.012, 0.693–1.269 vs 0.990, 0.710–1.237 g/cm2, p:n.s), whereas bone mineral density decreased significantly in nine patients who received placebo (0.984, 0.912–1.374 vs 0.914, 0.781–1.006 g/cm2, p<0.05). One patient who had received placebo developed a new vertebral fracture within 6 months after the end of the trial. This study indicates that cyclosporin A increases the biochemical parameters of bone remodeling, and prevents bone loss in patients with primary biliary cirrhosis. To assess whether cyclosporin A has any influence on the bones of patients with primary biliary cirrhosis, bone mineral density, vertebral fractures and biochemical and hormonal parameters of bone mineral metabolism were evaluated in 38 female patients with primary biliary cirrhosis who, 7 to 47 months previously, had been randomized to receive cyclosporin A (n=18) or placebo (n=20). Bone mineral density and vertebral fractures were reevaluated after 12 to 47 months in 19 of these patients (ten with cyclosporin and nine with placebo). Serum osteocalcin levels in patients taking cyclosporin (median, range: 7.8, 4.2–16 ng/ml) were similar to healthy female controls (6.0, 4.7–9.5 ng/ml), and significantly higher than in patients receiving placebo (5.4, 1.0–8.6 ng/ml, p<0.02). Patients treated with cyclosporin showed a higher urinary hydroxyproline/creatinine ratio (0.097, 0.025–0.138) than patients with placebo (0.031, 0.022–0.044) (0.05>p<0.1), and healthy controls (0.032, 0.021–0.048) (p<0.001). Urinary hydroxyproline was above normal levels in six of nine patients treated with cyclosporin. Circulating parathyroid hormone levels were also higher in patients treated with cyclosporin (4.3, 2.0–9.0 pmol/l) than in those with placebo (3.1, 1.1–5.1 pmol/l) (p<0.001), and healthy controls (2.9, 1.1–6.9 pmol/1) (p<0.001). In four patients treated with cyclosporin the parathyroid hormone levels were above normal values. No patient had renal failure. Among the 19 patients who were studied on two occasions, no significant bone mineral density changes were observed in ten patients treated with cyclosporin (1.012, 0.693–1.269 vs 0.990, 0.710–1.237 g/cm2, p:n.s), whereas bone mineral density decreased significantly in nine patients who received placebo (0.984, 0.912–1.374 vs 0.914, 0.781–1.006 g/cm2, p<0.05). One patient who had received placebo developed a new vertebral fracture within 6 months after the end of the trial. This study indicates that cyclosporin A increases the biochemical parameters of bone remodeling, and prevents bone loss in patients with primary biliary cirrhosis." @default.
• W2165167941 created "2016-06-24" @default.
• W2165167941 creator A5000600385 @default.
• W2165167941 creator A5020989510 @default.
• W2165167941 creator A5033003648 @default.
• W2165167941 creator A5048561028 @default.
• W2165167941 creator A5066827451 @default.
• W2165167941 creator A5079115636 @default.
• W2165167941 creator A5083542745 @default.
• W2165167941 date "1994-01-01" @default.
• W2165167941 modified "2023-10-16" @default.
• W2165167941 title "Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis" @default.
• W2165167941 cites W1501315399 @default.
• W2165167941 cites W1975759226 @default.
• W2165167941 cites W1977207568 @default.
• W2165167941 cites W1979035516 @default.
• W2165167941 cites W1979217337 @default.
• W2165167941 cites W1982981070 @default.
• W2165167941 cites W1986593290 @default.
• W2165167941 cites W1991003754 @default.
• W2165167941 cites W2001191355 @default.
• W2165167941 cites W2003697576 @default.
• W2165167941 cites W2007939595 @default.
• W2165167941 cites W2008443083 @default.
• W2165167941 cites W2012056124 @default.
• W2165167941 cites W2016053199 @default.
• W2165167941 cites W2041633275 @default.
• W2165167941 cites W2042688916 @default.
• W2165167941 cites W2044545913 @default.
• W2165167941 cites W2070815389 @default.
• W2165167941 cites W2109047974 @default.
• W2165167941 cites W2113803725 @default.
• W2165167941 cites W2128582518 @default.
• W2165167941 cites W2161412670 @default.
• W2165167941 cites W346957222 @default.
• W2165167941 cites W4255940022 @default.
• W2165167941 doi "https://doi.org/10.1016/s0168-8278(94)80132-0" @default.
• W2165167941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7963418" @default.
• W2165167941 hasPublicationYear "1994" @default.
• W2165167941 type Work @default.
• W2165167941 sameAs 2165167941 @default.
• W2165167941 citedByCount "37" @default.
• W2165167941 countsByYear W21651679412012 @default.
• W2165167941 countsByYear W21651679412014 @default.
• W2165167941 countsByYear W21651679412015 @default.
• W2165167941 countsByYear W21651679412016 @default.
• W2165167941 countsByYear W21651679412017 @default.
• W2165167941 countsByYear W21651679412018 @default.
• W2165167941 countsByYear W21651679412019 @default.
• W2165167941 countsByYear W21651679412020 @default.
• W2165167941 countsByYear W21651679412021 @default.
• W2165167941 countsByYear W21651679412022 @default.
• W2165167941 crossrefType "journal-article" @default.
• W2165167941 hasAuthorship W2165167941A5000600385 @default.
• W2165167941 hasAuthorship W2165167941A5020989510 @default.
• W2165167941 hasAuthorship W2165167941A5033003648 @default.
• W2165167941 hasAuthorship W2165167941A5048561028 @default.
• W2165167941 hasAuthorship W2165167941A5066827451 @default.
• W2165167941 hasAuthorship W2165167941A5079115636 @default.
• W2165167941 hasAuthorship W2165167941A5083542745 @default.
• W2165167941 hasConcept C126322002 @default.
• W2165167941 hasConcept C126894567 @default.
• W2165167941 hasConcept C131075544 @default.
• W2165167941 hasConcept C134018914 @default.
• W2165167941 hasConcept C142724271 @default.
• W2165167941 hasConcept C160160445 @default.
• W2165167941 hasConcept C170033053 @default.
• W2165167941 hasConcept C181199279 @default.
• W2165167941 hasConcept C204787440 @default.
• W2165167941 hasConcept C27081682 @default.
• W2165167941 hasConcept C2776541429 @default.
• W2165167941 hasConcept C2776886416 @default.
• W2165167941 hasConcept C2777214474 @default.
• W2165167941 hasConcept C2779797417 @default.
• W2165167941 hasConcept C2780306776 @default.
• W2165167941 hasConcept C2780366471 @default.
• W2165167941 hasConcept C2781208988 @default.
• W2165167941 hasConcept C519063684 @default.
• W2165167941 hasConcept C55493867 @default.
• W2165167941 hasConcept C71924100 @default.
• W2165167941 hasConcept C77411442 @default.
• W2165167941 hasConcept C86803240 @default.
• W2165167941 hasConcept C90924648 @default.
• W2165167941 hasConceptScore W2165167941C126322002 @default.
• W2165167941 hasConceptScore W2165167941C126894567 @default.
• W2165167941 hasConceptScore W2165167941C131075544 @default.
• W2165167941 hasConceptScore W2165167941C134018914 @default.
• W2165167941 hasConceptScore W2165167941C142724271 @default.
• W2165167941 hasConceptScore W2165167941C160160445 @default.
• W2165167941 hasConceptScore W2165167941C170033053 @default.
• W2165167941 hasConceptScore W2165167941C181199279 @default.
• W2165167941 hasConceptScore W2165167941C204787440 @default.
• W2165167941 hasConceptScore W2165167941C27081682 @default.
• W2165167941 hasConceptScore W2165167941C2776541429 @default.
• W2165167941 hasConceptScore W2165167941C2776886416 @default.
• W2165167941 hasConceptScore W2165167941C2777214474 @default.
• W2165167941 hasConceptScore W2165167941C2779797417 @default.
• W2165167941 hasConceptScore W2165167941C2780306776 @default.

• next